Related coverage linked through entity extraction aliases.
Aug 08, 2026
Physician-supervised clinics in Florida and Texas offer semaglutide and tirzepatide weight loss programs. Clinical trials show average weight loss of 15% with semaglutide and about 21% with tirzepatide. All-inclusive monthly plans start at $349.
May 06, 2026
Nereus (tradipitant) is now commercially available for prevention of motion-induced vomiting. Vanda has launched a phase 3 trial in GLP-1 users, building on phase 2 results showing a 50% relative reduction in vomiting.
Aug 01, 2026
One in eight U.S. adults now takes a GLP-1, and prescriptions among non-diabetics rose 700% since 2019. The market is projected to reach $200 billion by 2030, driving manufacturing investments and consumer food shifts.
Aug 01, 2026
A study of over 85,000 women found that insurance coverage and healthcare access significantly affect folic acid use, increasing preventable birth defect risks. The findings support fortification efforts, while a University of Houston initiative aims to address pharmacy access barriers.
May 07, 2026
Madrigal expands MASH pipeline with siRNA licensing deals from Arrowhead and Ribo. Ribo deal includes $60M upfront and up to $4.4B milestones; IND submissions planned for 2026.
Jun 20, 2026
Amgen shares have fallen 12.6% in three months despite relatively solid Q1 results, while Novo Nordisk maintains a 54.6% global GLP-1 market share. Both companies face pipeline competition and pricing pressures.
Jun 24, 2026
HHS launches broad initiative to boost US clinical trials amid global competition with China. FDA introduces real-time clinical trial monitoring and expedited programs. NIH Long COVID trials set to begin enrolling participants in summer 2026.
May 13, 2026
Eli Lilly reported positive phase 3b Together-PsO results for Taltz plus Zepbound in adults with plaque psoriasis and obesity or overweight. Separate meeting updates highlighted new oral plaque psoriasis therapies with biologic-like efficacy.
Apr 13, 2026
Arecor said it is in talks on a broader AT278 partnership as it targets a phase II trial start in the second half of 2026. The company also cited FDA feedback, Ligand financing and year-end cash of £6.1 million.
Mar 13, 2026
Recent studies examine safety profiles of GLP-1 receptor agonists, finding increased risk for nonscarring hair loss but improved survival in patients with brain metastases and type 2 diabetes.
Mar 06, 2026
Genentech announced positive Phase II results for CT-388, a dual GLP-1/GIP receptor agonist, showing 22.5% placebo-adjusted weight loss at 48 weeks in people with obesity. The treatment was well-tolerated with low discontinuation rates.
Feb 24, 2026
Triple-agonist drug retatrutide has demonstrated weight loss outcomes similar to bariatric surgery in Phase 3 trials. Research shows GLP-1 drugs work through brain-mediated appetite suppression and are effective even in genetic obesity.
Feb 15, 2026
Recent reviews highlight expanding clinical benefits of GLP-1-based therapies, including antiinflammatory actions across multiple organs and cardiovascular risk reduction, with combination approaches emerging for obesity treatment.
